Myosteatosis in Multiple Myeloma and Its Impact on Survival
Author Information
Author(s): Diallo Thierno D., Blessing Ariane Irma Luise, Ihorst Gabriele, Möller Mandy Deborah, Jungmann Pia M., Bamberg Fabian, Herget Georg, Wäsch Ralph, Engelhardt Monika, Neubauer Jakob
Primary Institution: University Medical Center Freiburg
Hypothesis
This study aimed to determine the prognostic value of myosteatosis assessed by CT for progression-free survival (PFS) and overall survival (OS) in multiple myeloma patients.
Conclusion
Myosteatosis is prevalent in newly diagnosed multiple myeloma patients and is associated with impaired overall survival.
Supporting Evidence
- The prevalence of myosteatosis was found to be 51% among the studied patients.
- Patients with myosteatosis had significantly lower progression-free survival and overall survival compared to those without.
- Myosteatosis was identified as an independent predictor of overall survival in multivariable analyses.
Takeaway
Myosteatosis, which is fat in the muscles, can make it harder for people with multiple myeloma to live longer, even if they have the same amount of muscle as others.
Methodology
This cohort study included newly diagnosed multiple myeloma patients who underwent CT imaging, with myosteatosis assessed through muscle radiodensity measurements.
Potential Biases
Potential bias due to the single-center design and retrospective data collection.
Limitations
The study is limited by its retrospective design and the need for further validation in larger cohorts.
Participant Demographics
Median age of 65 years, 63% male, with a BMI range of 14.1 to 42.5.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI [20.5–42.2] for PFS; 95% CI [51.3—90.2] for OS.
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website